Drug · CHEMBL1908370
FINAFLOXACIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. FINAFLOXACIN. Drugs and targets, record CHEMBL1908370. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1908370
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases5
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| acute otitis externa | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0001051 |
| Helicobacter pylori infectious disease | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0006781 |
| acute pyelonephritis | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0003529 |
| small cell lung carcinoma | Phase 3 | TTD | 1 | 0 | https://conductscience.org/library/drugs?q=MONDO_0008433 |
| urinary tract infection | Approval | TTD | 1 | 0 | https://conductscience.org/library/drugs?q=MONDO_0100338 |
Source Open Targets
Trials9
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01535599 | Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa | Phase 3 | 768 | 2014-06-18 | AL-60371 | Its name | ClinicalTrials.gov |
| NCT01535560 | Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa | Phase 3 | 589 | 2013-12-10 | AL-60371 | Its name | ClinicalTrials.gov |
| NCT01928433 | Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis | Phase 2 | 225 | 2017-06-20 | finafloxacin | Its name | ClinicalTrials.gov |
| NCT01910883 | Safety and Tolerability of Single and Multiple Intravenous Doses of Finafloxacin in Healthy Subjects | Phase 1 | 58 | finafloxacin | Its name | ClinicalTrials.gov | |
| NCT01904162 | Effect of Age and Gender on the PK and Tolerability of Finafloxacin | Phase 1 | 40 | finafloxacin | Its name | ClinicalTrials.gov | |
| NCT00722735 | Finafloxacin 300 mg Twice a Day (b.i.d.) Versus Ciprofloxacin 250 mg Twice a Day (b.i.d) in Patients With Lower Uncomplicated UTI (uUTI) | Phase 2 | 36 | finafloxacin | Its name | ClinicalTrials.gov | |
| NCT00723502 | Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients | Phase 2 | 30 | finafloxacin | Its name | ClinicalTrials.gov | |
| NCT01907867 | Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin | Phase 1 | 18 | finafloxacin | Its name | ClinicalTrials.gov | |
| NCT01908764 | Pharmacokinetic Study of AL-60371 Otic Suspension in Pediatric Subjects Following Tympanostomy Tube Surgery | Phase 1 | 0 | AL-60371 | Its name | ClinicalTrials.gov |
Comparisons in its trials2
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| AL-60371 vs Vehicle: serious adverse events | 0 of 344 | 1 of 342 | 686 | NCT01535599 | Trial comparisons |
| AL-60371 vs Vehicle: serious adverse events | 0 of 274 | 0 of 274 | 548 | NCT01535560 | Trial comparisons |
Papers from its trials6
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1908370
GET https://conductscience.org/api/drugs/v1/CHEMBL1908370/targets